Is immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 a useful surrogate for genotyping in colorectal adenocarcinoma?
Immunohistochemistry with VE1 is not a useful surrogate for genotyping in CRC. Although moderate or strong cytoplasmic staining is specific for BRAF V600E mutations, this antibody is insufficiently sensitive to serve as an effective screening tool.
In mice and humans, reduced p66Shc levels protect from obesity, but not from ectopic fat accumulation, glucose intolerance and insulin resistance.